Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9800490 | 1.00 | SLC7A5 (0.48) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL4586895 | 1.00 | SLC7A5 (0.48) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL28729833 | 1.00 | SLC7A5 (0.48) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL10667207 | 1.00 | SLC7A5 (0.48) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL20198745 | 0.86 | SLC7A5 (0.31) | SLC7A5 | |
| SCHEMBL9233627 | 0.83 | SLC7A5 (0.46) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL8845182 | 0.82 | SLC7A5 (0.48) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL27644223 | 0.81 | SLC7A5 (0.42) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL27644228 | 0.81 | SLC7A5 (0.42) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL393844 | 0.81 | GFPT1 (0.46) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106469-A2 | METHODS FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES | NEW YORK UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2012-07-05 | — | — | US | claimed |
| WO-2011032000-A2 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2011-03-17 | — | — | WO | claimed |
| WO-2006084322-A1 | TREATMENT METHOD FOR MODIFYING TISSUE PASSIVE ELECTRICAL CONDUCTANCE | MCLACHLAN CRAIG STEVEN (AU) | 2006-08-17 | — | — | WO | claimed |
| EP-0754023-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995024884-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1995-09-21 | — | — | WO | claimed |
| US-11872250-B2 | Methods for inducing an immune response by administering activated mesenchymal stem cells | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117202938-A | Variant Fc domains and uses thereof | 奇达拉治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116355814-B | Escherichia coli and application thereof in fermentation production of L-arginine | 欧铭庄生物科技(天津)有限公司滨海新区分公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116355814-A | Escherichia coli and application thereof in fermentation production of L-arginine | 欧铭庄生物科技(天津)有限公司滨海新区分公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-114728937-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11357850-B2 | Methods for treating breast cancer using INOS-inhibitory compositions | THE METHODIST HOSPITAL (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
| US-20030235589-A1 | Compositions and methods for systemic inhibition of cartilage degradation | OMEROS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| CN-1162918-A | Depressant of functions developed by molecule | KOYAMA SHOZO (JP) | 1997-10-22 | — | — | CN | disclosed |
| US-5028627-A | Controlling blood pressure during chemotherapy | CORNELL RESEARCH FOUNDATION, INC. (US) | 1991-07-02 | — | — | US | disclosed |
| EP-0230037-B1 | CYTOPROTECTIVE DERIVATIVES USEFUL IN ISCHEMIC DISEASES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | ITALFARMACO S.p.A. (IT) | 1991-03-06 | — | — | EP | disclosed |
| US-4789681-A | CARDIOPROTECTIVE AGENTS | ITALFARMACO S.P.A. (IT) | 1988-12-06 | — | — | US | disclosed |
| EP-0230037-A1 | Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them | ITALFARMACO S.p.A. (IT) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NOS2, NOS1, NOS3 | SLC7A5 1969/4885SLC1A1 2224/4885SLC1A3 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.